Technical Analysis for VXL - Vaxil Bio Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Range Bar | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% |
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Get a Trading Sidekick!
- Earnings date: Unknown
Vaxil Bio Ltd. Description
Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific antigen-based immunotherapy products. The Company offers its products from VaxHit technology, which uses the signal peptide (SP) domain in selected targets as core antigens. The Company's product, ImMucin, which has received orphan drug status and designed for the treatment of multiple myeloma (MM) cancer. The Company's ImMucin is in Phase I clinical trial to treat antigen specific immunotherapies; SPmAb2 and SPmAb6 are in pre-clinical stage to treat SP specific antibodies, and MTbuVax is in pre-clinical stage to treat anti-infectives.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Identification Clinic Drug Biotechnology Disease Cancer Therapy Biology Diseases Oncology Clinical Trial Immunology Antigen Immunotherapy Anti Infectives Antibodies Immune System Immunotherapies Infectious Diseases Peptide Antibody Infectious Disease Multiple Myeloma Vaccine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.035 |
| 52 Week Low | 0.005 |
| Average Volume | 158,659 |
| 200-Day Moving Average | 0.016 |
| 50-Day Moving Average | 0.013 |
| 20-Day Moving Average | 0.012 |
| 10-Day Moving Average | 0.011 |
| Average True Range | 0.002 |
| RSI (14) | 50.00 |
| ADX | 20.39 |
| +DI | 24.662 |
| -DI | 54.392 |
| Chandelier Exit (Long, 3 ATRs) | 0.009 |
| Chandelier Exit (Short, 3 ATRs) | 0.011 |
| Upper Bollinger Bands | 0.017 |
| Lower Bollinger Band | 0.007 |
| Percent B (%b) | 0.31 |
| BandWidth | 81.356 |
| MACD Line | -0.001 |
| MACD Signal Line | -0.001 |
| MACD Histogram | -0.0002 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.018 | ||||
| Resistance 3 (R3) | 0.017 | 0.013 | 0.016 | ||
| Resistance 2 (R2) | 0.013 | 0.011 | 0.014 | 0.016 | |
| Resistance 1 (R1) | 0.012 | 0.010 | 0.013 | 0.013 | 0.015 |
| Pivot Point | 0.008 | 0.008 | 0.009 | 0.009 | 0.008 |
| Support 1 (S1) | 0.007 | 0.006 | 0.008 | 0.008 | 0.005 |
| Support 2 (S2) | 0.003 | 0.005 | 0.004 | 0.004 | |
| Support 3 (S3) | 0.002 | 0.003 | 0.004 | ||
| Support 4 (S4) | 0.003 |
